Provident Financial Services, Inc.· PFS
🇺🇸 US · MidSP600NYSE
- Price
- $23.06
- Day
- -0.39%
- Mkt Cap
- $3.01B
- 52W Range
- $17.69 – $25.49
- Volume
- 1.72M
- Beta
- 0.77
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
TORONTO--(BUSINESS WIRE)---- $RPX.V #Canada--RPX Gold Inc. (“RPX Gold” or the “Company”) (TSXV: RPX) (OTCQB: RDEXF) is pleased to announce gold (“Au”) assay results from 25 drill holes totalling 4,336 metres (“m”) from its 2026 ongoing drilling program at the Wawa Gold Project in Ontario. The Company has now completed approximately two-thirds of the drilling meterage planned to support the prefeasibility study (“PFS”) and approximately half of its planned 20,000 m 2026 drill program. The results will be included.
Read full article
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from
Read full article
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller
Read full article
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e
Read full article
Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi
Read full article
Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo's ENHERTUÂ (fam-trastuzumab deruxtecan-nxki) demonstrated a stat
Read full article
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit
Read full article
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab alone Results are most pronounced in HPV+ patients, with cORR (80.0% vs 33.3%), CR rate (30.0% vs 0%), and PFS6 improvement (90.0% vs 33.0%) vs pembrolizumab alone Inhibrx will expand the Phase 2 study by approximately 50 HPV+ patients and may serve as a potential pathway to accelerated approval Positive results support large expansion opportunities into highly immunogenic tumors and combination with cancer vaccines SAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
Read full article
TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Wallbridge Mining Company Limited (TSX: WM, OTCQB: WLBMF) (“Wallbridge” or the “Company”) is pleased to announce final assay results from seven holes completed during the 2026 metallurgical drilling program at the Fenelon Gold Project. These results provide further confidence in the geological and grade continuity of the deposit while delivering the high quality of sample material needed to better characterize gold recovery characteristics and metallurgical performance across the Fenelon deposit. The drilling targeted areas considered for underground mining in the March 2025 Preliminary Economic Assessment (“PEA”) and provided representative samples for metallurgical characterization and variability testing in support of the Pre-feasibility Study (“PFS”) currently underway.
Read full article
Provident Financial (PFS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read full article